News
After setbacks with psychedelics, phase 2b data with GH Research's GH001 for treatment-resistant depression could lift confidence in the category.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback